IMARA Inc. (IMRA)
$4.7
+0.16 (+3.52%)
Rating:
Recommendation:
-
Symbol | IMRA |
---|---|
Price | $4.7 |
Beta | 1.050 |
Volume Avg. | 0.11M |
Market Cap | 123.550M |
Shares () | - |
52 Week Range | 0.974-5.261 |
1y Target Est | - |
DCF Unlevered | IMRA DCF -> | |
---|---|---|
DCF Levered | IMRA LDCF -> | |
ROE | -64.98% | Strong Sell |
ROA | -76.16% | Strong Sell |
Operating Margin | - | |
Debt / Equity | 3.17% | Neutral |
P/E | - | |
P/B | 2.16 | Strong Buy |
Latest IMRA news
About
Download (Excel)IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.